PAM Gene Variants Cut Ozempic Response in 10%
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Stanford Medicine researchers found that ~10% of people carry PAM gene variants causing 'GLP-1 resistance' — they have higher circulating GLP-1 hormone levels but reduced biological response, a counterintuitive finding published March 29 in Genome Medicine.
- Senior authors Anna Gloyn (Stanford) and Markus Stoffel (ETH Zurich) led a decade of work combining human trials, mouse experiments, and clinical trial data showing PAM variant carriers respond poorly to GLP-1 receptor agonists.
- In a combined analysis of three trials with 1,119 participants, ~25% of non-carriers hit target HbA1c levels after six months of GLP-1 drug treatment, versus only 11.5% of those with the p.S539W variant and 18.5% with p.D563G.
- Gloyn's team confirmed the PAM variants did NOT affect response to other common diabetes drugs (sulfonylureas, metformin, DPP-4i), confirming the resistance is specific to GLP-1 receptor pharmacology.
- Two pharma-funded trials using longer-acting GLP-1 formulations showed no difference between carriers and non-carriers, suggesting longer-lasting drugs may bypass the resistance mechanism.
- The biological mechanism remains unsolved — the PAM defect does not affect how GLP-1 binds its receptor or how signals are transmitted; the resistance occurs further down the pathway, which Gloyn called 'the million-dollar question.'
- The study did not determine whether the variants affect weight loss outcomes from Ozempic and Wegovy; only two trials included weight data and showed no clear difference, leaving that question open for future research.
Why it matters: More than one in four Type 2 diabetes patients take GLP-1 drugs, and an estimated 10% of the population may carry a genetic variant that blunts their effectiveness — meaning those patients could spend months on a drug that fails to control blood sugar before clinicians switch them. A simple genetic test could fast-track those patients to alternative medications, saving time, money, and uncontrolled disease progression.
